Aposense Pipeline: From Platform to Products
Aposense Pipeline: From Platform to Products
Aposense Pipeline: From Platform to Products
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Molecular Imaging of Apop<strong>to</strong>sis:<br />
Phase 2: Design and Status<br />
CA004<br />
Brain<br />
metastases<br />
∆<br />
∆<br />
SRS<br />
24h<br />
8 weeks<br />
Diagnosis &<br />
Eligibility<br />
Baseline<br />
Ana<strong>to</strong>mical<br />
Imaging<br />
Baseline<br />
ML-10<br />
Imaging<br />
Treatment<br />
Follow-up<br />
ML-10<br />
Imaging<br />
Follow-up<br />
Ana<strong>to</strong>mical<br />
Imaging<br />
1w<br />
Combined Chemo-Radiation<br />
7 weeks<br />
8 weeks<br />
CA007<br />
H&N and<br />
NSCLC<br />
∆<br />
∆<br />
Timeline<br />
CA004 Brain metastases treated with SRS<br />
Recruitment<br />
Completed<br />
CA007 H&N treated with chemo-radiation Oc<strong>to</strong>ber 2012<br />
CA007 Lung treated with chemo-radiation Postponed, image<br />
analysis<br />
Results<br />
November 2012<br />
February 2013<br />
Safety status:<br />
212 procedures<br />
106 patients<br />
No related<br />
adverse event<br />
Forward-Looking Information Notice: The Company’s assessments and estimates regarding the above timeline depend,<br />
among other fac<strong>to</strong>rs, on continuation of present patient recruitment rate, sufficient clinical data and successful clinical trials<br />
results analysis, and other risk fac<strong>to</strong>rs which apply <strong>to</strong> the Company’s activity, as described on Company’s annual reports
Change language